#Japan #Tokyo #Longevity #TIME TRAVELER #IPAS2025

Securing a Bright Future: TIME TRAVELER's Selection for IPAS2025

TIME TRAVELER Co., Ltd., a breakthrough biotechnology startup specializing in longevity, has been chosen as a participant in the Intellectual Property Acceleration Program IPAS2025. This highly esteemed program, administered by the Japan Patent Office, aims to support innovative startups in strengthening their intellectual property (IP) strategies in alignment with business goals. With a robust focus on health and longevity, TIME TRAVELER stands at the forefront of research and development, espousing cutting-edge technologies to unlock the secrets of aging and promote longer, healthier lives.

About IPAS2025

Initiated in 2018, the IPAS program has empowered over 104 startups across six years, providing specialized guidance in intellectual property management. From 2024 onward, the program will be run by the National Center for Industrial Property Information and Training (INPIT), emphasizing the importance of integrating IP strategies into startup business frameworks. The program engages a dedicated team composed of business and IP specialists who work alongside startups over a five-month period. This hands-on approach involves mentoring and support to validate and enhance business strategies while simultaneously crafting agency-aligned IP strategies.

Through this initiative, TIME TRAVELER will receive invaluable support from expert teams in business and intellectual property. The focus will be on fortifying a coherent IP portfolio that aligns closely with the company’s business aspirations, especially in the realms of innovative drug development and health care. By honing in on genes that promote aging, TIME TRAVELER is set to gain a significant competitive edge as it accelerates its market offerings domestically and internationally.

TIME TRAVELER Co., Ltd.: A Brief Overview

Founded on January 22, 2024, and headquartered in Taito, Tokyo, TIME TRAVELER is driven by pioneering research from the Institute of Quantitative Biosciences at the University of Tokyo, led by Professor Emeritus Tohru Akiyama. The startup focuses on developing novel drugs utilizing various modalities, including antibodies, small molecules, and nucleic acid medications, specifically targeting aging-related diseases and cellular aging processes. This unique approach aims to inhibit the mechanisms tied to cancer cell proliferation and aging-related genes, encouraging breakthroughs in the development of anti-cancer and anti-aging pharmaceuticals.

Moreover, TIME TRAVELER is exploring innovative health care applications by developing supplements featuring plant and algae-derived exosomes, thus broadening its impact in the health sector. With capital exceeding 150 million yen, the company is poised for remarkable growth and influence, combining advanced science with tangible health outcomes.

Looking Ahead

The selection for the IPAS2025 program signifies a leap toward future growth for TIME TRAVELER. By leveraging insights from IP experts and advisors, the startup aims to reinforce its position in the competitive landscape of longevity and healthcare. Through the formation of effective strategies, TIME TRAVELER not only aspires to improve the lives of individuals through scientific innovation but also sets a precedent in the aging-related biotechnology field.

As they embark on this journey through the IPAS program, TIME TRAVELER is positioned to impact society positively by enhancing health and life expectancy, signaling a hopeful future for researchers and audiences alike keen on the possibilities of a healthier tomorrow.

For more information related to TIME TRAVELER or inquiries from media representatives, reach out via email at [email protected] or visit their official website at ttraveler.jp.